FDA Approves 2nd Over-The-Counter Drug To Counteract Fentanyl , Opioid Overdoses

The Food and Drug Administration has approved a second over-the-counter drug to counteract  opioid overdoses, including those caused by fentanyl.
The drug is RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray was approved as the second over-the-counter, or nonprescription, nasal spray for the treatment of a known or suspected opioid overdose.
The drugmaker, Harm Reduction Therapeutics, will determine when it will  be available and its cost to consumers.
“We know naloxone is a powerful tool to help quickly reverse the effects of opioids during an overdose. Ensuring naloxone is widely available, especially as an approved OTC product, makes a critical tool available to help protect public health,” FDA Commissioner Robert M. Califf, M.D., said in a statement. “The agency has long prioritized access to naloxone products, and we welcome manufacturers of other naloxone products to discuss potential nonprescription development programs with the FDA.”